Deadline Tracker: Could 2026 Be A “Record Year” For Approvals? FDA On Pace For 60 NMEs After Nine Approved In September; Merck/Daiichi Withdrawal Of Lung Cancer Therapy Thins Line-Up For October

You must be a logged-in member of this site to view this article.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Alternatively, if your organization already has a license and you do not yet have an account, please click here to request access.